drugset / Trial / NCT05102006

A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

NCT05102006

Phase 1/2 Completed 80 enrolled Nanjing Leads Biolabs Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, multicenter Phase Ib/II clinical study to evaluate the safety, tolerability, PK characteristics, immunogenicity and efficacy of LBL-007 in combination with Toripalimab in Treatment of Advanced Malignant Tumors.

Timeline

Start
2021-11-30
Primary completion
2024-05-22
Completion
2024-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcestobart Monoclonal antibody Intravenous
Subject Toripalimab Monoclonal antibody Intravenous

Indications